Imprimis Pharmaceuticals Inc (IMMY)

[sloan14]

In most cases, phase 3 trial have a pilot (small group), if they are successful, than the move to a bigger study with a partner. IMO

Ketotransdel® is comprised of a transdermal formulation of ketoprofen, an NSAID, and the Company's innovative patented proprietary Transdel™ drug delivery system. Ketotransdel® penetrates the skin barrier to reach the targeted underlying tissue where it exerts its prolonged localized anti-inflammatory effect.

This drug may minimize systemic exposure, therefore, resulting in fewer concerns pertaining to gastrointestinal, renal, cardiovascular and other adverse systemic effects, which are associated with orally administered NSAIDs.

This drug may help address certain safety concerns in the market and potentially provide physicians and patients with a much needed alternative for pain.

We are seeking a commercial partner for Ketotransdel®, and are actively pursuing discussions with U.S. and foreign based potential partners with sales and marketing infrastructures. If you are interested to discuss a potential licensing opportunity for Ketotransdel® please contact John Lomoro, CFO, at [phone] or at [e-mail]